Sudarshan Pharma (SUDARSHAN) | Financial Analysis & Statements
Sudarshan Pharma Industries Ltd. Small-cap Basic Materials
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
1.5B
Gross Profit
160.5M
11.05%
Operating Income
101.6M
6.99%
Net Income
39.6M
2.73%
EPS (Diluted)
₹0.16
Balance Sheet Metrics
Total Assets
4.0B
Total Liabilities
2.7B
Shareholders Equity
1.3B
Debt to Equity
2.06
Cash Flow Metrics
Revenue & Profitability Trend
Quarter Income Flow
Jun 30, 2025
Annual Income Flow
2025
Sudarshan Pharma Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 5.1B | 4.6B | 4.6B | 3.6B | 1.9B |
| Cost of Goods Sold | 4.4B | 4.2B | 4.3B | 3.4B | 1.8B |
| Gross Profit | 651.0M | 410.6M | 297.2M | 191.9M | 140.5M |
| Gross Margin % | 12.9% | 8.9% | 6.4% | 5.4% | 7.3% |
| Operating Expenses | |||||
| Research & Development | - | - | - | - | - |
| Selling, General & Administrative | 81.9M | 40.8M | 30.4M | 14.6M | 12.4M |
| Other Operating Expenses | 108.2M | 146.1M | 77.7M | 36.4M | 36.0M |
| Total Operating Expenses | 190.1M | 186.8M | 108.2M | 51.1M | 48.3M |
| Operating Income | 379.0M | 215.7M | 144.2M | 102.0M | 64.2M |
| Operating Margin % | 7.5% | 4.7% | 3.1% | 2.9% | 3.3% |
| Non-Operating Items | |||||
| Interest Income | 5.5M | 7.9M | 4.9M | 1.7M | 253.0K |
| Interest Expense | 141.0M | 89.4M | 45.9M | 28.7M | 28.6M |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | 216.3M | 152.3M | 95.0M | 71.9M | 35.7M |
| Income Tax | 56.8M | 37.7M | 24.6M | 18.9M | 9.0M |
| Effective Tax Rate % | 26.2% | 24.8% | 25.9% | 26.2% | 25.3% |
| Net Income | 159.5M | 114.6M | 70.4M | 53.0M | 26.7M |
| Net Margin % | 3.2% | 2.5% | 1.5% | 1.5% | 1.4% |
| Key Metrics | |||||
| EBITDA | 407.7M | 254.2M | 152.3M | 110.3M | 71.7M |
| EPS (Basic) | ₹0.66 | ₹0.48 | ₹0.55 | ₹2.20 | ₹1.11 |
| EPS (Diluted) | ₹0.66 | ₹0.47 | ₹0.55 | ₹2.20 | ₹1.11 |
| Basic Shares Outstanding | 24065887 | 238652083 | 128507840 | 24065887 | 24065887 |
| Diluted Shares Outstanding | 24065887 | 238652083 | 128507840 | 24065887 | 24065887 |
Income Statement Trend
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Sudarshan Pharma Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 5.5M | 1.4M | 117.2M | 2.4M | 12.5M |
| Short-term Investments | 15.0M | 15.0M | - | - | - |
| Accounts Receivable | 1.6B | 1.2B | 815.1M | 734.8M | 603.9M |
| Inventory | 1.4B | 857.4M | 745.7M | 468.7M | 239.6M |
| Other Current Assets | 275.4M | 316.4M | - | 1.0K | - |
| Total Current Assets | 3.3B | 2.4B | 2.0B | 1.3B | 876.4M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 200.5M | 205.3M | 0 | 0 | 0 |
| Goodwill | 73.1M | 93.3M | 9.0M | 1.2M | 2.3M |
| Intangible Assets | 3.3M | 6.2M | 9.0M | 1.2M | 2.3M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 42.5M | - | - | -1.0K | -1.0K |
| Total Non-Current Assets | 675.6M | 415.5M | 338.6M | 79.4M | 116.2M |
| Total Assets | 4.0B | 2.8B | 2.3B | 1.4B | 992.6M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 918.3M | 567.2M | 918.9M | 737.5M | 442.2M |
| Short-term Debt | 1.6B | 943.5M | 213.2M | 240.7M | 244.5M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 10.5M | 3.3M | 3.3M | -2.0K | 2.0K |
| Total Current Liabilities | 2.6B | 1.6B | 1.2B | 1.0B | 712.2M |
| Non-Current Liabilities | |||||
| Long-term Debt | 104.6M | 104.9M | 127.9M | 65.2M | 53.2M |
| Deferred Tax Liabilities | 2.9M | 183.0K | 1.8M | 1.4M | 1.4M |
| Other Non-Current Liabilities | 3.3M | 1.0K | - | 1.0K | - |
| Total Non-Current Liabilities | 112.3M | 105.9M | 130.3M | 67.1M | 55.3M |
| Total Liabilities | 2.7B | 1.7B | 1.3B | 1.1B | 767.5M |
| Equity | |||||
| Common Stock | 240.7M | 240.7M | 240.7M | 97.5M | 95.5M |
| Retained Earnings | - | - | - | - | - |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 1.3B | 1.1B | 1.0B | 297.8M | 225.1M |
| Key Metrics | |||||
| Total Debt | 1.7B | 1.0B | 341.0M | 305.9M | 297.7M |
| Working Capital | 751.5M | 807.5M | 801.4M | 285.4M | 164.2M |
Balance Sheet Composition
Sudarshan Pharma Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 216.3M | 152.3M | 95.0M | 71.9M | 35.7M |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | - | - | - | - | - |
| Working Capital Changes | -385.7M | 239.0M | -601.5M | -427.8M | -315.2M |
| Operating Cash Flow | 8.5M | 472.8M | -457.4M | -323.8M | -247.4M |
| Investing Activities | |||||
| Capital Expenditures | -47.5M | -37.8M | -138.0M | -16.6M | -13.2M |
| Acquisitions | -635.0K | -10.0M | 0 | - | - |
| Investment Purchases | - | - | - | - | - |
| Investment Sales | - | - | - | - | - |
| Investing Cash Flow | -47.1M | -65.2M | -138.0M | -16.6M | -13.2M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | -7.2M | - | - | - |
| Debt Issuance | - | - | - | - | - |
| Debt Repayment | - | - | - | - | - |
| Financing Cash Flow | 11.1M | -8.6M | -6.8M | 64.4M | 5.1M |
| Free Cash Flow | 304.8M | 39.7M | -426.0M | -53.9M | 14.7M |
| Net Change in Cash | -27.5M | 399.1M | -602.2M | -276.0M | -255.6M |
Cash Flow Trend
Sudarshan Pharma Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
35.73
Price to Book
5.61
Price to Sales
1.12
Profitability Ratios
Profit Margin
3.26%
Operating Margin
5.93%
Return on Equity
12.13%
Return on Assets
3.96%
Financial Health
Current Ratio
1.29
Debt to Equity
155.50
Beta
0.69
Per Share Data
EPS (TTM)
₹0.84
Book Value per Share
₹5.35
Revenue per Share
₹26.00
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| SUDARSHAN | 7.3B | 35.73 | 5.61 | 12.13% | 3.26% | 155.50 |
| Navin Fluorine | 322.4B | 57.84 | 8.89 | 10.99% | 17.74% | 32.68 |
| Deepak Nitrite | 230.5B | 43.19 | 4.18 | 12.85% | 6.71% | 22.41 |
| Ghcl | 46.2B | 9.54 | 1.33 | 17.89% | 16.60% | 2.66 |
| Styrenix Performance | 41.0B | 24.75 | 3.29 | 20.14% | 4.66% | 44.08 |
| Chemplast Sanmar | 38.6B | 210.40 | 2.02 | -5.34% | -7.01% | 96.73 |
Financial data is updated regularly. All figures are in the company's reporting currency.





